Skip to content

Homepage

Author: NEKTAR THERAPEUTICS

Posted Date:

June 26, 2026

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEKTAR THERAPEUTICS

June 26, 2026
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEKTAR THERAPEUTICS

June 3, 2026
Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York

NEKTAR THERAPEUTICS

May 29, 2026
Nektar Therapeutics Reports First Quarter 2026 Financial Results

NEKTAR THERAPEUTICS

May 26, 2026
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEKTAR THERAPEUTICS

May 26, 2026
Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets

NEKTAR THERAPEUTICS

May 25, 2026
Nektar Therapeutics Announces Closing of $373.8 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

NEKTAR THERAPEUTICS

May 25, 2026
Nektar Therapeutics Announces Pricing of Upsized $325 Million Public Offering

NEKTAR THERAPEUTICS

May 24, 2026
Nektar Therapeutics Announces Proposed Public Offering

NEKTAR THERAPEUTICS

May 24, 2026
52-Week Topline Results from 16-Week Blinded Treatment Extension of REZOLVE-AA Demonstrate Deepening of Responses in Severe-to-Very-Severe Alopecia Areata with Rezpegaldesleukin

NEKTAR THERAPEUTICS

May 24, 2026

1 2 3